MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with an initial focus on industrial safety applications in South America's mining sector, according to a recent article. The company has appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
The AI platform uses voice analysis to predict intoxication, drawing on over 50 million data points to achieve high accuracy. MindBio is developing an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software for detecting drug and alcohol intoxication via the human voice. The technology targets a range of enterprise environments, including mining, aviation, construction, and law enforcement.
Felipe Leyton brings experience in national drug policy and workplace safety. He helped design and implement Chile's 'Zero Tolerance' alcohol-impaired driving law as part of the country's alcohol prevention framework and played a role in establishing Chile's roadside drug testing program introduced in 2019. His appointment reflects MindBio's strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
The full article is available at https://ibn.fm/JBNVq. For more information about MindBio Therapeutics, including the latest news and updates, visit the company's newsroom at https://ibn.fm/MBQIF.
MindBio is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice.
